Frontlight ResearchEarly access
CompletedNo phase
ACP Max™ PRP System for Knee Osteoarthritis: A Feasibility Trial
Key facts
- Who runs it
- Arthrex, Inc.
- Where
- Danville, Knoxville, and Winston-Salem, United StatesSee the 3 sites
- Trial code
- Status
- Completed
- People taking part
- 45 people enrolled
- Started
- 13 May 2024
- Ended
- 9 Feb 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- ACP Max™
- Depo-Medrol®
- Record updated
- 18 February 2026
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 28 criteriaShow less
Who can take part
- Subject voluntarily decides to participate and signs the consent form
- Subject is ≥ 18 to 75 years of age
- Subject presents with symptomatic knee OA despite at least 6 months of one of the following conservative treatments; oral medications, analgesics, and/or anti-inflammatory medications
- Subject has documented radiographic evidence of OA in the tibiofemoral or patellofemoral compartment of the target knee (Kellgren-Lawrence Grades II-III), using radiographs performed within 12 weeks of screening
- Subject has a WOMAC pain score (WOMAC A) of at least 8 out of 20 and at least moderate degree of difficulty (a score of 2) for at least 2 questions on performing daily activities
- Subject consents to a washout period of NSAIDs and analgesics 7 days before each study visit (except low-dose aspirin for prevention of cardiovascular disease)
- Subject has a Body Mass Index ≤ 35 kg/m2
Who cannot take part
- Subject has received an IA injection of corticosteroids in the target knee within 4 months prior to screening
- Subject did not achieve initial pain relief from prior corticosteroid injections
- Subject has received an IA injection of HA in the target knee within 6 months prior to screening
- Subject has received an IA injection of PRP in the target knee at any time prior to screening
- Subject had prior open surgery on the target knee within 12 months or knee arthroscopy within 6 months
- Subject plans to participate in other clinical trials involving medical or surgical intervention in the next 12 months
- Subject with plans to undergo any elective orthopedic surgery in the next 12 months
- Subject requires pain management therapy not related to the target knee (with the exception of acetaminophen)
- Subject has clinically 3+ effusion of the target knee (stroke test grading system)
- Subject has a history of coagulopathy
- Subject has an inflammatory disease of either knee other than OA
- Subject which, in the investigator's opinion, has an underlying medical condition(s) that could interfere with the evaluation of the outcome
- Subject with any condition (including cognitive impairment) that, in the investigator's opinion, might interfere with the evaluation of the study objectives
- Subject has an infection at the affected joint
- Subject has a history of major trauma to the target knee within one year
- Subject has a known hypersensitivity to Depo-Medrol and its constituents
- Subject has Grade I or IV in the target knee according to the Kellgren-Lawrence grading scale
- Subject has significant (> 10°) valgus or varus deformities as evidenced by standard of care x-ray
- Subject has joint pain reflected by a VAS score of > 35 mm out of 100 mm scale in the contralateral knee at the time of screening
- Subject with a positive pregnancy test or breastfeeding
- Subject has rheumatoid arthritis or gout
Where in United States
- Spectrum Medical, Inc.Danville, United States
- AMR KnoxvilleKnoxville, United States
- The Center for Clinical ResearchWinston-Salem, United States
About the trial
What the trial wants to find out
This study is a prospective, multicenter (up to 4 sites), randomized, double-blind, two-arm study. Forty-five (45) patients will be randomized to receive a single 4-6 ml intra-articular (IA) injection of either the output of ACP Max™ (n=30) or 6 ml of Depo-Medrol® (methylprednisolone acetate) (n=15).
The 2 groups in the trial
- ACP Max™Treatment being tested
Single 4-6 ml intra-articular (IA) injection of the output of ACP Max™
- 40 mg of methylprednisolone acetateExisting treatment, for comparison
Single IA injection of 40 mg of methylprednisolone acetate (1 ml of solution) mixed with 5 ml of Normal Saline for a total of 6 ml.
Treatment: Depo-Medrol®
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 18 February 2026